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Abstract-Brain homogenates from young rats were assayed for their ability to synthesize cerebrosides 
from radioactive UDP-galactose or UDP-glucose and ceramide. A comparison of galactose transfer 
with ceramides made from different 2-hydroxy acids showed that the shortest one tested (C,) was 
by far the best acceptor, while the poorest contained 18 carbon atoms; longer fatty acids were better 
than CIS. Glucosyltransferase, on the other hand, showed rather little chain length specificity or dis- 
crimination against hydroxy acid ceramides. 
Synthetic compounds analogous in structure to ceramides were tested as inhibitors of the sugar 
transferases. Some were found to act as sugar acceptors themselves, particularly amides of DL-erythro-1- 
phenyl-2-amino-1,3-propanediol. Some amides were good inhibitors of glucosyltransferase, particularly 
decanoyl norephedrine, decanoyl threo-l-phenyl-2-amino-1,3-propanediol and decenoyl phenylalaninol. 
The secondary amine analogous to the first of these, N-decyl norephedrine, was also very effective. 
No strong inhibitors of galactosyl transferase were found, although octanoyl o-threo-p-nitrophenyla- 
minopropanediol showed promise (42% inhibition at 0.3 mM). Octanoyl phenylalaninol was nearly as 
good an inhibitor; the inhibition appeared only after a lag period. 
It is suggested that the glucosyltransferase inhibitors might he useful in therapy of Gaucher's disease, 
by reducing the degradative load normally falling on glucocerebrosidase. 
BRAIN contains glycosyltransferases which have the 
ability to  form gluco- and galactocerebroside from 
the corresponding uridine nucleotide sugars and cera- 
mide (MORELL & RADIN, 1969; BASU et al., 1968, 
1971). The galactosyltransferase shows a marked pre- 
ference for ceramides made from 2-hydroxy fatty 
acids, while the glucosyltransferase utilizes the hyd- 
roxy and nonhydroxy ceramides with roughly equal 
ability (SHAH, 1971; MORELL et al., 1970). This report 
presents details of the relative effectiveness of the 
enzymes with ceramides made from fatty 'acids of 
different chain lengths, with and without a D- or 
This work was supported by grants NS-03192 and GB 
36735 from the United States Public Health Service and 
National Science Foundation. 
Postdoctoral trainee, Mental Health Research Insti- 
tute, supported by grant MH-07417 from the National In- 
stitute of Mental Health. Present address: Department of 
Cellular Physiology, Walter Reed Army Institute of 
Research, Washington, DC 20012, U.S.A. 
'Present address: Meyer L. Prentis Cancer Center, 
Detroit, MI 48201, U.S.A. 
Present address: Department of Biochemistry, The 
Chicago Medical School, Chicago, IL 60612, U.S.A. 
Abbreviations used: Fatty acids are described digitally 
by chain length and number of double bonds (e.g.: 10:0 
is decanoic acid). The letter h in front of the abbreviation 
indicates the presence of a 2-hydroxy group. PAPD is 
l-phenyl-2-amino-1,3-propanediol. Ceramide is the fatty 
acid amide of sphingenine. 
L-hydroxyl group. (The D-configuration is the natural 
one in hydroxy cerebrosides.) 
The primary purpose of this study was to search 
for effective inhibitors of the enzymes in an effort to 
control the metabolism of the glycolipids. In particu- 
lar, it seemed possible that one might be able to  ame- 
liorate Krabbe's and Gaucher's diseases by slowing 
cerebroside biosynthesis in patients by means of suit- 
able inhibitors. In these genetic disorders, hydrolysis 
of the two cerebrosides is seriously impaired and it 
is plausible to attempt reducing the load placed on 
the hydrolases by inhibiting cerebroside synthesis. 
This hypothesis could be examined by producing a 
model form of the genetic disorders in rats by means 
of hydrolase inhibitors-an attempt now under 
trial-and then correcting the disorders with synthe- 
tase inhibitors. 
In the course of testing potential inhibitors, we 
found that some of the compounds acted as acceptors 
of the sugar moieties, forming abnormal cerebrosides. 
MATERIALS AND METHODS 
Stereochemistry of substrates and inhibitors 
Sphingolipids have as their backbone the amino glycol, 
sphingosine (sphingenine), in which the C-2 and C-3 car- 
bon atoms have the D-configuration. We have made a large 
assortment of related compounds in which a small alipha- 
tic group or a phenyl group replaces the long aliphatic 
chain of sphingenine. In some instances the hydroxyl group 
on the C-1 or C-3 position has been omitted. Some of 
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the basic structures are shown here: 
1 2 1  
CH3(CH2),,CH=CH -0- CH-CH, 
I l l  
OH NH OH 
I l i  
OH NH OH 
0- erythro-sphingenine 
D-erythro-I-phenyl-2- ornino- I, 3-proponediol 
(0-erythro- PAPD) 
0-  threo-PAPD 
NH OH 
0-I-phenyl- 2- amino - 3-propanot 
NH OH (0- phenylolaninol) 
y - - f W - C H ,  
OH NH 
In some cases we used the DL-form rather than the 
D-form. In others the benzene ring possessed a nitro group 
in the para position. Note that the bend in the backbone 
of sphingenine produced by the trans double bond is par- 
tially mimicked by the bend introduced by the benzene 
ring. The rule for numbering carbon atoms requires that 
the phenyl derivatives be numbered differently than in 
sphingenine, as shown above, but in our previous papers 
we have used the same system for both to emphasize the 
steric relationships. The nitrogen atoms are shown with 
incomplete substituents to indicate the presence in our 
compounds of a carboxylic acid or an n-alkyl group. 
Synthesis of substrates and inhibitors 
Several amino alcohols were obtained as  gifts (ARORA 
& RADIN, 1972~) .  Norisoephedrine (~-threo-l-phenyl-2- 
amino-1-propanol) was from ICN-K & K Laboratories, 
Cleveland, OH. DL-2-Methylphenylalanine was from ICN 
Pharmaceuticals, at the same address. Nervonic acid was 
a gift from Dr. K. K. Carroll and tmns-2-decenoic acid 
was from Research Organic/lnorganic Chemical Corp., 
Belleville, NJ. Most of the other reagents were from 
Aldrich Chemical Co.: Milwaukee, WI. 
Some of the compounds were prepared for other studies 
(HYUN et al., 1975; ARORA et a/., 1973). In  the case of 
the hydroxy acid ceramides, the starting material was IIL- 
hydroxy acid (prepared hy bromination and hydrolysis of 
fatty acids) which was used to acylate natural (D) sphingo- 
sine. The resultant DD- and Lo-isomers were separated by 
chromatography on silica gel columns, the former coming 
out just after the latter as expected from the TLC separ- 
D- erythro-I-phenyl-2- amino-I-proponol 
(0- norephedrlne) 
ations. The solvent used was 2-SX isvpropanol in chloro- 
form, depending on the fatty acid chain length. 
Decenoic acid amides were synthesized via the M-hyd- 
roxy succinimide 2-decenoate ester (LAPIDOT et al., 1967). 
One of the amides was converted to the 2,3-epoxy deriva- 
tive by refluxing 0.91 g decenoyl norephedrine (3  mmol) 
with 0.67 g of SS% pure m-chloroperoxybenzoic acid 
(3.3 mmol) in 10 ml dichloroethane for 8 h. The solution 
was washed with NaOH and water, evaporated to dryness 
and the residue triturated with hexane to produce 0.70g 
(73% of theory) of crystals melting at 75-6°C. The mixed 
m.p. with the starting material was 65-70°C and the ori- 
ginal amide’s m.p. was 92-3°C. Curiously, the epoxy com- 
pound showed the same RF as ,the original amide (0.71 
with chloroform-methanol-HOAc, 90: 2: 8) but it could be 
differentiated from the original compound because spray- 
ing with an epoxide indicator (OESCH er a/., 1971) yielded 
a positive reaction. The elemental analysis, NMR data  and 
i.r. spectrum confirmed the oxirane structure and absence 
of the trans double bond of the original amide. 
Phenylalanine and 2-methylphenylalanine were reduced 
to the corresponding alcohols with sodium bis(2-methox- 
yethoxy)aluminum bydride (‘Redal’, Aldrich Chemical 
Co.). The amino acid was dried in a desiccator, then 4.64 g 
(28 mmol) were added to a reflux system together with 
25 ml of dry benzene. Under nitrogen, 31 ml of reducing 
agent (112 mmol) were added and the suspension was re- 
fluxed 3 h. The resultant solution was cooled, 25 ml of 40% 
aqueous NaOH were added slowly, the mixture was satu- 
rated with NaCl and the benzene layer was removed. The 
aqueous layer was extracted with 7 x 50ml ether and the 
organic layers were pooled and evaporated to a small 
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volume. Addition of benzene and cooling yielded 2.47g 
of crystalline phenylalaninol (58% of theory). TLC of the 
product revealed a ninhydrin-positive spot corresponding 
to L-phenylalaninol from Fluka AG, Switzerland, together 
with a trace spot just above the amino alcohol (TLC 
solvent: chloroform-methanol-water-29% ammonia 
280:70:6:1). A charring spray showed the same two spots. 
In the case of 2-methylphenylalanine the yield was some- 
what lower. 
Enzyme assuys 
The enzyme source was brain from 16-day-old rats of 
the Sprague-Dawley strain, and the assay procedure was 
carried out as described before (BRENKERT & RADIN, 1972; 
RADIN, 1972). The incubation medium, slightly modified, 
contained 0.1 M-Tris-HCI, pH 7.4, 15 mM-MgCI2, 2 mM- 
EDTA, 1 mM-dithioerythritol and 0.16 mM-UDP-galactose 
or -glucose labelled in the sugar moiety. In the case of 
UDP-Glc, 2 mM-ATP was also included. Each assay tube 
contained 1 mg of lyophilized brain homogenate or 0.5 mg 
of acetone-washed lyophilized microsomes in a total 
volume of 0.2 ml. Where an inhibitor was to be tested, 
the compound was added to the incubation tube in solu- 
tion and solvent removed before addition of the other 
assay components. 
In most assays, the radioactive cerebroside was isolated 
by solvent partitioning, but in some cases the lipids were 
separated by TLC and the radioactive products located 
by exposure to X-ray films. The radioactive powder was 
removed from the plate by scraping into glass scintillation 
vials, and the silica gel was dissolved by a modification 
of the method of SHAW et nl. (1971). The powder was mois- 
tened with 0.4 ml water, 0.3 ml of concentrated H F  was 
added, the vial was shaken on a gyrotory platform and 
10 ml of scintillation solvent was added (100ml Triton 
X-100 + 1.2 g PPO + 80 mg dimethylPOPOP + 300 ml 
xylene). One might expect this use of glass vials with HF  
to destroy the vials, but we found that they could be reused 
after simple washing. 
The enzyme reactions were found to proceed at a con- 
stant rate for 90min and the rates were proportional to 
the amount of enzyme used (within the range used). When 
galactosyltransferase was assayed, 0.2 mg of a mixture of 
hydroxy ceramides (derived from cerebrosides) was added 
as sugar acceptor. In the case of glucosyltransferase, 0.2 mg 
of mixed nonhydroxy ceramides was used for whole brain 
incubations and 0.05 mg for microsomes, since the higher 
substrate concentration yielded slightly lower activities 
with microsomes. 
The data reported are the average values from triplicate 
determinations made simultaneously. In some instances, 
where the activities seemed particularly interesting or un- 
expected, the assays were repeated once or twice more on 
different days with different batches of enzyme; the degree 
of inhibition observed with such repeated assays could 
differ by 5%. In interpreting the significance of a result, 
one should compare the values obtained with homologs 
of different chain length or with a different level of sub- 
strate. 
RESULTS 
Substrate specijcity of galactosyltransferase 
In a comparison of the effectiveness of ceramides 
containing different hydroxy acids (Table l), it was 
found that the best acceptor was the shortest one 
tested, made from ~-h7:0 .  The poorest one was the 
one made from ~-h18:0. The h7:O ceramide was 
about 7-times more effective than the natural mixture, 
which contained h24:0, h23:0, h22:0, h18:O and h24:l 
as the major components. As noted before (MORELL 
& RADIN, 1969), the non-hydroxy ceramides were very 
poor substrates. Of particular interest is the trend 
with increasing chain lengths above 18 carbons: the 
h22:O and h24:O ceramides were more effective than 
hl8:O. A similar strong preference for unusually short 
fatty acid derivatives was reported for the brain 
enzyme which forms phosphatidyl inositol (BENJAMINS 
& AGKANOFF, 1969). 
In some cases the unnatural ceramides, made with 
L-hydroxy acids, were tested. ~ -h7 :0  was 29",, as 
TABLE 1. GALACTOSYLATION OF DIFFERENT CERAMIDES 
Fatty acid Cerebroside formed (nmol/h per mg) 
~ - h 7 : 0  
D-h10:0 
~ - h 1 4 : 0  
D-h18:O 
~ - h 2 2  10 
~ - h 2 4 : 0  
Mixed hydroxy 
























The data in the first column were obtained with 0.1mg of microsomal 
powder and 0.2mg of ceramide, incubated as in Methods. The data in 
the right-hand column were obtained similarly, but with 0.5 mg microsomes 
and 0.05mg ceramide. In the case of D-h7:0, the incubation was for only 
60 min. Galactosyltransferase activity without added ceramide was 0.10 
nmol/h per mg. 
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TABLE 2. GLUCOSYLATION OF DIFFERENT CERAMIDES 























Incubations were carried out with 0.5 mg microsomal powder and 
0.05 mg ceramide as in Methods. Glucosyltransferase activity without 
added ceramide was 2.0 nmol/h per mg. 
active as the D-isomer, ~ - h l O : 0  was 21% as effective 
as ~-1110:O and ~-h22:0  was 51% as effective as 
~-h22:0 .  
The data in Table 1 were obtained from equal 
weights of the different ceramides, so the molar con- 
centration was inversely related to the chain length. 
Thus one might attribute some of the observed differ- 
ences to the differing molar concentrations. However, 
several studies of activity vs concentration showed 
that we were using levels of substrate that were close 
to saturating. 
Examination of some of the radioactive products 
by TLC (chloroform-methanol-water 144: 25 :2.8) and 
radioautography showed, when mixed hydroxy cera- 
mides were used, that the primary products were a 
double band in the cerebroside region corresponding 
approximately to h24: 0 and h18 : 0 cerebrosides. In 
addition there was a faint, diffuse band which could 
be due to short chain hydroxy cerebrosides (such as 
h10: 0) and a band considerably below the hydroxy 
cerebroside region. This last band had been noticed 
in previous studies; it is stable to alkaline methano- 
lysis and does not appear in incubations made with 
synthetic ceramides. Presumably it is derived from an 
impurity in the mixed ceramides. It amounts to about 
15% of the total radioactivity in the chloroform layer 
produced in the partitioning assay, so the data 
obtained with mixed ceramides are all a little too 
high. 
By means of radioautography it could be shown 
that the radioactive product formed from each hyd- 
roxy ceramide exhibited the expected RF and relative 
intensity expected from the radioactivity found in the 
chloroform layer. When ~ ~ 4 2 4 :  0 ceramide was tested 
as substrate, the expected radioactive band was pro- 
duced but there was also a slightly radioactive band 
that was faster moving (RF 0.53 vs 0.40). While one 
might expect to see some of the unnatural iso-meric 
cerebroside, formed from the L-isomer, the relative 
migration rate seems too fast (HAJRA et al., 1966). 
Substrate specijicity of glucosyltran$erase 
This enzyme, in striking contrast to the galactosyl- 
transferase, exhibited rather little specificity with re- 
spect to the length of the fatty acid chain in the cera- 
mide (Table 2). Both D- and L-hydroxy acid ceramides 
were utilized with similar efficiency. 
Examination of the radioactive glucosides by thin- 
layer plate radioautography showed that the endo- 
genous ceramides yielded a cluster of cerebrosides 
around 18:O cerebroside, but each added ceramide 
yielded primarily the expected narrow radioactive 
band arising from that particular precursor. Thus the 




















































Data shown are per cent inhibition of the control activity obtained without added 
inhibitor. A plus sign indicates a higher activity than the control. Incubations were 
carried out with 0.3 mM inhibitor and 1 mg of brain powder as described in Methods. 
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TABLE 4. AMIDES OF p-NITRO PAPD AS 1NHIBITORS 
Fatty PAPD Galactose Glucose 










































































Incubations were carried out with 0.3 mM inhibitor and 1 mg brain powder as in 
Methods. Data show per Cent inhibition of control activity. Data in parentheses were 
obtained similarly but with only 0.02 mg of ceramides as sugar acceptor. 
data in Table 2 largely represent the true synthesis 
of the expected cerebrosides. 
Amides of PAPD as inhibitors of galactosyltran$erase 
Relatively small effects were observed with these 
analogs of ceramide (Table 3). Decanoyl DL-erythrO- 
PAPD, which had been found to be a good inhibitor 
of cerebroside galactosidase (ARORA & RADIN, 1972a), 
was essentially inert against the transferase. The best 
inhibitor in this series was the bromoacetyl amide, 
previously mentioned as an inhibitor of this enzyme 
(ARORA & RADIN, 1972b). In that study the inhibitory 
effectiveness had been somewhat greater, possibly 
because microsomes had been used in the assay. 
The last compound in the table, a ceramide analog 
made from a DL-hydroxy acid, seemed to stimulate 
galactose transfer. However, as noted later in this 
paper, some of the hydroxy acid amides acted as  sub- 
strates themselves, more effectively than the natural 
hydroxy ceramides. 
While bromoacetyl PAPD showed promise as an 
inhibitor, 2-bromophenylacetyl PAPD (which has a 
more reactive bromine atom) was virtually inert. 
PAPD amides containing a p-nitro group showed 
promise and were studied in greater detail (Table 4). 
As with the natural substrates, chain length of the 
fatty acid was a significant factor and only the 
octanoyl derivative of D-threo-PAPD was a good in- 
hibitor. Insertion of a double bond in the decanoyl 
derivative enhanced its effectiveness. The dichloroace- 
tyl compound, the commercially useful antibiotic, 
chloramphenicol, was virtually inactive. Unlike the 
h12:O amide listed in Table 3, the h12:O amide in 
Table 4 was quite inert. 
In the experiments where low concentrations of cer- 
amide substrate were used (data in parentheses), in- 
hibitory action was enhanced, indicating that these 
substances acted as competitive inhibitors. 
Amides of’ phenylalaninol as inhibitors of galactosyl- 
transferase 
l-Phenyl-2-amino-3-propanol is an analog of 
sphingosine in which the secondary alcohol group is 
lacking so there can be no distinction between threo 
and erythro isomers. Amides of this material (Table 
5) showed some promise as inhibitors, the cinnamoyl 
TABLE 5. AMIDES OF PHENYLALANINOL AS INHIBITORS 











L 25 (23) 
L 30 
L 27 (30) 
L 1 
L 38 (53) 
D 0 
D 27 










Data obtained with 1 mg brain homogenate as in Methods. Data 
in parentheses indicate per cent inhibition produced with 1/10 the 
regular amount of ceramide acceptor. 
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TABLE 6. INHIBITION BY AMIDES OF 1-PHENYL-2-AMINO-1-PROPANOL 
Fatty Galactose Glucose 
acid Isomer transfer transfer 
24:O DL-Erythro + 19 36 
16:O uL-Erythro + 10 36 (59) 
14:O DL-Erythro 0 37 (70) 
1o:o DL-Erythro 12 (24) 69 (82) 
12:o rx-Erythro 0 47 (77) 
8:O oL-Erythro __ 
6:O DL-Erythro 0 7 
36 
1O:l  DL-Erythro 8 44 (65) 
Benzoyl m-Erythro 11  24 
2-Br 6:O DL-Erythro 3 15 
1 O : O  epoxy* DL-Erythro 8 54 
12:o ri-Threo 5 47 (53) 
lo:o D-Threo 5 43 
8:O D-Threo 6 3 1 (52) 
33 1O:l D-Threo - 
Cinnamoyl u-Threo 4 22 (29) 
Amides evaluated with 1 mg of brain powder. See legends to other 
* This is the compound formed by epoxidation of 2-decenoyl nore- 
tables for details. 
phcdrine 
derivative being the best. Curiously, the 10:0 amide 
of the D-isomer was inert, while the 10:l amide 
showed some activity. There is some sign also with 
the L-isomer that the unsaturated amide is more effec- 
tive than the saturated one. 
Unexpectedly, two of the compounds tested with 
a low level of substrate showed no improvement in 
inhibitory power, suggesting that they act noncompe- 
titively. The others tested this way showed the 
expected competition with ceramide. 
Amides of 1-phenyl-2-amino-1-propanol as yalactosyl- 
trunsferase inhibitors 
This series of compounds is derived from norephed- 
rine (the DL-erythro isomer) and norisoephedrine, a 
naturally occurring substance (D-threo). All the com- 
pounds tested (Table 6) were found to be virtually 
inert or slightly stimulatory. In the case of the latter 
amides, it is not likely that they acted as galactose 
acceptors since the amides do not possess a primary 
alcohol group. It seems from the negative findings 
here that the galactosyltransferase, when acting on 
the natural substrate, has a site which binds the pri- 
mary alcohol group. However, there must be some 
recognition of the aromatic analog since a test o f  the 
decanoyl DL-erythro compound with a low concen- 
tration of ceramide produced appreciable inhibition, 
24%. We prepared N-decanoyl norephedrine contain- 
ing a catechol group [(3,4-dihydroxyphenyI)propano- 
lamine] in the hope that it might bind to the galacto- 
syltransferase and then oxidize and bind to the 
enzyme irreversibly. The binding was apparently 
slight since it produced only 8% inhibition. 
Aliphatic amides und miscellaneous amides tested with 
galactos~ltransferase 
Several aliphatic amino alcohols were acylated, 
generally with decanoic acid, but tests with the galac- 
tosyltransferase system showed only small effects 
(Table 7). Decanoyl 2-methy1-2-amino-1-propano1, 
which had proved to be a good stimulator of cerebro- 
side galactosidase (ARORA & RADIN, 19724, produced 
no effect. The ceramide made with sphingosine and 
2-bromostearic acid. an analog of hydroxy ceramide, 
showed slight inhibitory power. A compound not 
shown in this table, the decanoyl amide of o-amino- 
phenyl-8-glucoside, produced 16% inhibition. 
TABLE 7. EFFECT OF ALIPHATIC AMIDES ON CER~BKOSIIE SYNTHESIS 
Fatty 








2-Br 2:O CH,C(CHj)(NH)CH*OH 
Phenyl- 
2-Br 18:0 Sphingosine 
2 13 
+ 2  15 
+9 25 
+ 3  19 
2 34 
- + 5  
11 16 
~~ ~ 
Data values are in per cent inhibition or  (+) stimulation obtained with whole brain powder. 
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TABLE 8. SECONDARY ALKYL AMINES AS INHIBITORS 
Aromatic 
substituent Amino alcohol 
Galactose Glucose 
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The amines were tested with 1 mg brain powder as enzyme source. 
Secondary irmines us inhibitors ofgalactosyltransferase 
Various amino alcohol analogs of sphingosine were 
alkylated, generally with 1-bromodecane or 1,2-epox- 
ydecane (Table 8). Comparison with the analogous 
amides (Tables 3 and 4) shows that the amines were 
distinctly less active, indicating the importance to the 
enzyme of the amido arrangement. Indeed, the 
secondary amines were generally found to be stimula- 
tory when the alkyl group was long enough. There 
was no correlation of the stimulations with the con- 
figuration of carbons 2 and 3, so it seems likely that 
the effect was due to an interaction at a site other 
than the catalytic one. 
G[ucosyltruns&ase and iimides of aromatic analogs of 
sphingosine 
The structural requisites for inhibition of the gluco- 
syltransferase were found to be much less restrictive 
than for the galactosyltransferase. Perhaps this is to 
be expected from the lower specificity of the glucose 
enzyme with respect to nonhydroxy and hydroxy cer- 
amides, as well as the fatty acid chain length in the 
ceramide (Tables 1 and 2). However, there was 
marked sensitivity to the configuration of the C-1 car- 
bon atom, which can be seen in Table 3 (amides of 
threo-PAPD were inhibitory while amides of erythro- 
PAPD, with or without a para substituent, were sti- 
mulatory). There was also distinct sensitivity to  the 
configuration of the C-2 carbon, since the D-threo 
compound was twice as effective as the L-threo com- 
pound in the case of the octanoyl amide of nitro- 
PAPD (Table 4). As noted below, it is likely that the 
stimulations were actually due to utilization of the 
amides as glucose acceptors. 
Omitting the C-1 hydroxyl group (Table 5) 
amides acted as competitive inhibitors. Placing a 
methyl group on the C-2 carbon atom increased the 
effectiveness of the decanoyl compound. 
The best inhibitors of glucose transferase were 
obtained when the C-3 hydroxyl group was omitted 
(Table 6). Here there was a distinct chain length 
effect, with decanoic acid having the optimal length. 
In this series decenoic acid was inferior to decanoic 
acid. Further tests with different concentrations of 
N-decanoyl DL-norephedrine showed that maximal 
inhibition was attained at 0 . 6 m ~  (75% with 0.2mg 
ceramide as acceptor) and significant inhibition was 
still detectable at 0.05 mM inhibitor (1 6%). 
Insertion of an oxirane ring (‘1O:O epoxy’) did not 
greatly affect the inhibitory ability of decanoyl nore- 
phedrine. It is possible that this inhibitor might 
slowly form a covalent bond, such as an ester linkage, 
with a sensitive site in the glucosyltransferase. 
Of the aliphatic amides tested (Table 7), the mono- 
hydroxy branched methyl compound showed the 
most promise. The 2-methyl group definitely en- 
hanced the inhibition, a point that may also be true 
in the phenylalaninol series (Table 5) .  
Glucnsyltransferuse inhibition by secondary amines 
Unlike the case with galactosyltransferase, this 
enzyme generally interacted with the reduced amides 
(alkyl amines) rather much like its interaction with 
the corresponding amides. For example, decanoyl 
norephedrine (Table 6) was an excellent inhibitor of 
the glucose enzyme and the N-decyl analog (line 1, 
Table 8) was also excellent. However, decanoyl erythro- 
PAPD (Table 3) stimulated glucose transfer while 
N-decyl erythro-PAPD inhibited it (Table 8). 
enhanced the inhibitory effect. Use of 2-decenoic acid 
instead of decanoic acid further enhanced the effect 
with both the L- and D-isomers. A low ceramide con- 
centration also enhanced the effect, indicating that the 
Of 
As noted above, some of the amides, particularly 
those most closely resembling ceramide in structure, 
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seemed to stimulate sugar transfer. A study of 2-hyd- 
roxy acid amides showed that almost all produced 
this effect with both sugar nucleotides. The effect was 
smaller when the C-1 hydroxyl was omitted or in- 
verted and the C-2 carbon had the L-configuration. 
Further tests in which the natural substrates were 
omitted showed that radioactive lipid was formed 
anyway when the analog was present. As noted with 
the natural substrates, galactosyltransferase acted far 
better with analogs made from hydroxy acids while 
glucosyltransferase acted approximately equally well 
with hydroxy and nonhydroxy acid amides. 
Radioautographic analysis of TLC plates made 
with the radioactive products showed that the analogs 
produced glycosides migrating more slowly than the 
natural cerebrosides. For example, the use of micro- 
somes incubated with mixed hydroxy ceramides and 
labelled UDP-gal yielded the usual double hydroxy 
cerebroside band arising from the C-18 and C-24 clus- 
ters (RF 0.42 and 0.47 with chloroform-methanol- 
water 24:7:1). When the h14:O amide of erythro- 
PAPD was included in the incubation, a strong band 
with RF 0.30 also appeared, corresponding to the 
region just below phosphatidyl ethanolamine. Cur- 
iously, despite the use of an amide made from a DL- 
hydroxy acid, only a single radioactive spot appeared, 
in contrast to the double band we found with DL-hyd- 
roxy acid amides of sphingosine. 
With both UDP-Glc and UDP-gal, the amount 
of radioactivity found in each spot was depressed by 
the presence of the second amide. That is, the natural 
ceramides competed with formation of the unnatural 
’cerebrosides’ and the ceramide analog competed with 
the formation of the natural cerebrosides. This mutual 
inhibition is consistent with the assumption that both 
amides competed for the same catalytic site on each 
sugar transferase. In all the experiments in which an 
aromatic analog was the sole added sugar acceptor, 
we found the unnatural substance to be a better 
acceptor than the mixture of ceramides ordinarily 
used as substrate. 
From the data in Table 4, it is apparent that the 
glucosyltransferase rejects acyl PAPD as sugar accep- 
tor when a nitro group is present on the benzene 
ring. Nevertheless the nitro compounds must bind to 
the enzyme since they acted as inhibitors. 
Parametric studies of the inhibitory effects 
The data reported thus far in this paper were 
obtained with a single inhibitor concentration and a 
single time point. Several of the most active sub- 
stances were tested in greater detail. 
Octanoyl D-threo-nitroPAPD, our best galactosyl- 
transferase inhibitor, was found to give the same 
degree of inhibition at all time points up to 90min. 
This indicates that it acts by a simple, reversible com- 
bination with the enzyme. On the other hand, 
octanoyl ~-phenylalaninol showed a marked lag in 
the development of its inhibitory action. The radioac- 
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FIG. 1. Glucocerebroside formation by brain microsomes 
as a function of ceramide weight. Each incubation tube 
contained 0.5 mg of microsornal powder and was incubated 
as in Methods with labelled UDP-Glc. Curve A :  
decanoyl sphingosine as glucose acceptor (M.W. 436). 
Curve B:  nervonoyl sphingosine as acceptor (M.W. 648). 
tive products were examined by TLC and were found 
to be only the usual cerebrosides, with no evidence 
for a galactosyl derivative of the inhibitor. Thus the 
lag period could not be attributed to gradual forma- 
tion of a cerebroside analog which was a potent in- 
hibitor. A similar study with the glucocerebroside 
synthesizing system and epoxydecanoyl norephedrine 
(Table 6) showed that the inhibitor gradually deacti- 
vated the enzyme; after 90min there was little ad- 
ditional synthesis of cerebroside. This finding is con- 
sistent with the idea that the epoxy ring reacted cova- 
lently with the sugar transferase. 
Several tests were made with substrates of different 
fatty acid chain lengths to make sure that our assays 
were carried out under proper (substrate-saturating) 
conditions. One such comparison (Fig. 1) with gluco- 
setransferase and two somewhat different ceramides 
(1O:O and 24:l) showed that nervonoyl sphingosine 
was a better glucose acceptor at low concentrations 
but a poorer one at high concentrations. With both 
ceramides there was an optimal concentration of cera- 
mide, probably due to a coating effect, since the lipids 
were applied to the dried microsomes by evaporation 
from benzene solution. No doubt it is difficult for 
the labelled UDP-Glc and cofactors to contact the 
enzyme when an excessively thick coating of ceramide 
has been applied. This effect also explains the inver- 
sion in activities seen in Fig. 1 at about 0.3 mM sub- 
strate since 24:l ceramide must be somewhat less sol- 
uble in water than 10:0 ceramide. 
DISCUSSION 
Our finding that the galactosyltransferase does best 
with very short hydroxy ceramides (Table 1) could 
mean that such substrates do indeed exist and that 
such cerebrosides also exist. This suggestion is sup- 
ported by examination of radioautographs made from 
TLC plates containing radioactive cerebrosides that 
were formed from hydroxy ceramides of ‘natural’ ori- 
gin. That is, these ceramides were prepared chemically 
(CARTER et a/., 1961) from assorted cerebrosides that 
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had been isolated from beef nervous tissue. The 
radioautographs showed a small amount of radioacti- 
vity in the region of the very short hydroxy cerebro- 
sides. 
An alternative explanation is that the rates of galac- 
tose acceptance depend on the lipophilefiydrophile 
ratio of the ceramide. That is, a ceramide possessing 
a short fatty acid may be more readily brought into 
contact with the catalytic site of the enzyme, while 
the long chain ceramides tend to aggregate in the 
form of relatively large insoluble particles which can- 
not readily make contact with the catalytic site. Such 
an effect, if significant, would obscure the true prefer- 
ences of the enzyme. An argument against the impor- 
tance of physical differences in ceramides of different 
chain length comes from the data of Table 2: gluco- 
syltransferase showed little chain length specificity 
despite the wide range of fatty acids. Moreover, h24:O 
was a better acceptor than the shorter chain h18:O 
ceramide in the case of galactosyl transfer. 
With either explanation, there is still the question 
as to whether the galactosyltransferase truly uses hyd- 
roxy ceramides as its substrate in the intact animal. 
Attempts in several laboratories to find hydroxy cera- 
mide in fresh brain have failed, although nonhydroxy 
ceramide was readily observed and MORELL et al. 
(1970) have proposed that the rate-limiting step in 
hydroxy cerebroside synthesis is the hydroxylation 
reaction. This means that hydroxy ceramide is galac- 
tosylated as fast as it is formed, and thus does not 
accumulate to a detectable degree. This explanation 
is supported by the observation (ULLMAN & RADIN, 
1972) that brain contains enzymes which can acylate 
sphingosine with CoA esters of 2-hydroxy acids; these 
enzymes are specific for chain length of the fatty acid 
and are different from the enzymes which make non- 
hydroxy ceramides. That a-hydroxyiation is indeed 
a slow reaction is indicated by the studies with rat 
brain by HOSHI & KISHIMOTO (1973). CARTER & 
KANFER (1974) have attempted to detect hydroxy cer- 
amides by injecting rats with labelled serine but failed 
to isolate detectable amounts of radioactivity. They 
consequently suggested that hydroxy ceramides are 
not normally formed or converted to cerebroside. 
However, such an interpretation requires the unsup- 
ported assumption that an undetectably small 
amount of an intermediate must nevertheless possess 
a detectable amount of radioactivity. 
While we were disappointed that none of the galac- 
tosyltransferase inhibitors seemed to be unusually 
effective, it was encouraging to see that the glucosyl- 
transferase inhibitors showed fairly good specificity 
with respect to the two enzymes. A disappointment 
with respect to specificity was the finding that amides 
of erythro-PAPD are good inhibitors of galactocere- 
brosidase (ARORA et a[., 1973) yet are substrates for 
the two sugar transferases. Administration of such 
amides to animals might result in accumulation of 
galactocerebroside and its aromatic analog, as well 
as aromatic analogs of glucose-containing sphingoli- 
pids, such as gangliosides. The influence of such ac- 
cumulation in rapidly dividing tissues, such as cancer 
cells, might be interesting to determine. 
The enhanced formation of galactolipid when 
secondary amines were added to the incubations 
(Table 8) is particularly intriguing, since the amines 
might be acting as galactose acceptors. We have pre- 
viously shown that N-hexyl galactosyl sphingosine is 
a fairly good inhibitor of galactocerebrosidase (ARORA 
et ul., 1973) and it is likely that N-alkyl PAPD galac- 
toside would also be a good inhibitor. Thus adminis- 
tration to an animal of N-alkyl PAPD might cause 
particularly enhanced accumulation of the abnormal 
galactocerebroside. 
This study, like all searches for enzyme inhibitors, 
is in need of additional attempts. Leads for further 
syntheses can be seen from the observations recorded 
in this study and we are still synthesizing additional 
analogs, while commencing in viuo tests of some of 
the best inhibitors. 
Our finding that hydroxyheptanoyl sphingosine 
was an excellent galactose acceptor raises the ques- 
tion as to whether we should shift to this as the nor- 
mal substrate for assaying the galactosyltransferase 
of rat brain and for evaluating new ceramide analogs 
as inhibitors. The short chain ceramide is easier to 
prepare, especially since ethyl 2-bromo-heptanoate is 
now commercially available (Sapon Laboratories), 
and its K ,  is not much different than that of the 
mixed ceramides; thus competitive inhibitors could 
be detected readily. The high cost of the assays, due 
to the expensiveness of UDP-gal, would be apprecia- 
bly diminished. 
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